Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Narrows Net Loss in 2003; 4Q Revenues, R&D Spend Falls

NEW YORK, Jan. 28 (GenomeWeb News) - Millennium Pharmaceuticals of Cambridge, Mass., yesterday reported a net loss of $146 million for the fourth quarter ending Dec. 31, 2003.

 

The loss was attributable, in part, the company said, to restructuring charges, which totaled $191 million on a net loss of $484 million for the year, compared to $590 million in 2002.

 

The company reported revenues of $85 million for the fourth quarter, compared to $97 million for the same period in 2002, and revenues of $434 million for the year, compared to $353 for the year. The company spent $111 million on research and development for the period, compared to $147 million for the year-ago quarter and reported an R&D spend of $489 for the year, compared to $511 million for 2002.

 

As of Dec. 31, the company reported $915 million in cash, cash equivalents, and marketable securities on hand, as well as $106 million in principle amount of convertible debt.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.